Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DOROTHY: Dose Reduction of Docetaxel-Based Chemotherapy in Vulnerable Older Women With Early-Stage Breast Cancer
NCT06042569Phase 2Recruiting
- Sponsor
- City of Hope
- Start
- Sep 2024
- Primary completion
- Sep 2031
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of docetaxel in breast cancer, sponsored by City of Hope. Started Sep 2024; status: recruiting.
02
Drugs
docetaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06042569.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06042569.